Funding Contract executed between the Österreichische Forschungsförderungsgesellschaft mbH (FFG) as Funding Agency and ARSANIS Biosciences GmbH Helmut-Qualtinger-Gasse 2 Company Register No. 354305m as Funding Recipient
Exhibit 10.29
FFG
Project no. 841918/30000 SCK/SAI
executed between the
Österreichische Forschungsförderungsgesellschaft mbH (FFG)
as Funding Agency
and
ARSANIS Biosciences GmbH
Xxxxxx-Xxxxxxxxxx-Xxxxx 0
0000 Xxxxxx
Company Register No. 354305m
as Funding Recipient
§ 1 Funding grant
| 1.1 | On the basis of the funding application “Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections” received on 5/2/2013 via eCall, and based on the expert decision of the Advisory Board in the meeting of 6/26/2013, funding is granted for the following project: |
Project number: 841918
eCall number: 3875436
Pre-project number: 837128
Project name (purpose of the agreement):
Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections
Program: Base program
./2
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0000 Xxxxxx |
Phone +43(0)5 7755 - 0 Fax +43 (0) 5 7755 -97900 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a Comm. Court Vienna |
FFG
Project no. 841918/30000 SCK/SAI
Page 2
§ 2 Project period
| 2.1 | The overall project period shall begin on 5/13/2011 and end on 4/30/2014. |
| 2.2 | Funding of the entire project by the FFG depends on the results as demonstrated in the submitted reports, the continued fulfillment of the evaluation and decision criteria, the budget available to the Funding Agency and a new positive funding decision. |
§ 3 Funding period
| 3.1 | The funding period of this project shall begin on the approval date 5/1/2013 and end on 4/30/2014. |
§ 4 Type and amount of funding
| 4.1 | Funding will be awarded in the following form over the funding period specified in § 3: |
| Type of funding |
Maximum amount | |||||||
| Subsidy granted by the FFG |
EUR | 585,300.00 | ||||||
| Loan granted by the FFG |
EUR | 2,503,000.00 | ||||||
Loan conditions
| Interest rate |
0.75% p.a. per current account | |
| Redemption date: |
6/30/2020 | |
| Redemption amount: |
EUR 2,503,000.00 | |
| Interest and loan collection: |
automatic debit procedure | |
| Interest payment due: |
semi-annually in arrears and/or upon maturity of the loan |
| 4.2 | The funded financing of the project is 70.0% of the verifiable and eligible project costs. The Funding Recipient shall finance the remaining project costs. Based on the plan data, the cash value of the funding is EUR 1,025,071.00, i.e. 23.2% related to the eligible project costs pursuant to Point 5.1. |
| 4.3 | The maximum funding cash value according to the applicable Community Framework for public R&D subsidies is 45.0%. |
| 4.4 | A decrease in the eligible project costs shall entail a prorated cutback of the funding. |
| 4.5 | The eligible project costs pursuant to § 5 and the costs reported by way of interim and/or final accounts shall not be considered approved until a review by the FFG. The final amount of the approved overall project costs as well as the funding shall be determined only after the completion of the project in the course of the final audit. |
./3
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0000 Xxxxxx |
Phone +43(0)5 7755 - 0 Fax +43 (0) 5 7755 -97900 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a Comm. Court Vienna |
FFG
Project no. 841918/30000 SCK/SAI
Page 3
§ 5 Eligible costs
| 5.1 | The funding is based on following eligible project costs: |
| Personnel costs |
EUR | 959,600.00 | ||||||
| Cost of use of R&D infrastructure |
EUR | 36,300.00 | ||||||
| Cost of materials |
EUR | 300,000.00 | ||||||
| Third-party costs |
EUR | 3,093,200.00 | ||||||
| Travel costs |
EUR | 22,900.00 | ||||||
| Total eligible costs |
EUR | 4,412,000.00 |
| 5.2 | All costs attributable to the project which are incurred directly, actually and additionally to the normal operating expenses) for the duration of the funded research activities are eligible costs. Additional supplementary provisions regarding eligible costs may be found in the FFG Guidelines, the FFG Guidelines Base Program and the “Guide for the Treatment of Project Costs in Funding Applications and Reports”. |
| 5.3 | Major changes to the cost structure shall require the prior written approval of the FFG. |
| 5.4 | The turnover tax payable on the costs of eligible services is not an eligible cost. However, it is considered an eligible cost component if it can be demonstrated that said turnover tax must be borne in actual fact and without recourse by the Funding Recipient, i.e. if it is not entitled to the input tax deduction. The refundable turnover tax—in whatever way—is not eligible even if it is not actually refunded to the Funding Recipient. If the tax office considers funds which are taxable under the Turnover Tax Xxx 0000, Federal Gazette No. 663 not as funding but as a contractual compensation for services provided by the Funding Recipient to the Funding Agency, and if the Funding Recipient owes turnover tax on such funds to the tax office, the contractual compensation shall be regarded as gross compensation. An additional, separate reimbursement of the turnover tax—for whatever legal reason—shall thus be excluded. |
| 5.5 | If the amortization period of an asset (Sec. 285 ABGB [Allgemeines Bürgerliches Gesetzbuch (Civil Code)]) purchased for the implementation of the project exceeds the funding period, the depreciation costs shall be eligible in the manner described in the FFG Guidelines – Base Program and the “Guide for the Treatment of Project Costs in Funding Applications and Reports”. |
| 5.6 | Funds provided by the Funding Agency may not be used for the creation of reserves or accruals under the Income Tax Xxx 0000, Federal Gazette No. 400. The funds may be used only for goods and services and for the purposes described in the funding application. |
| 5.7 | In case of new applications, the eligible costs incurred after receipt of the funding application may be approved. In case of follow-up applications, the earliest date for cost approval shall be the beginning of the funding period stated under § 3. |
| 5.8 | The costs of drawing up the agreement or the bank transfer expenses incurred by the Funding Recipient or its affiliates shall be borne by them and shall not be eligible costs. |
./4
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0000 Xxxxxx |
Phone +43(0)5 7755 - 0 Fax +43 (0) 5 7755 -97900 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a Comm. Court Vienna |
FFG
Project no. 841918/30000 SCK/SAI
Page 4
| 5.9 | The Funding Agency reserves the right to postpone, cut back or suspend the disbursement of funding if and as long as circumstances prevail which might make it impossible to guarantee the proper execution of the promoted project (e.g. if the documentary evidence for costs is not adequate). |
§ 6 Project-specific terms and conditions
| 6.1 | Project-specific special terms and conditions |
| 1. | Before the disbursement of the 1sr installment, the remaining funding must be documented in writing within 12 weeks from the issue date of the contract. |
| 2. | “Other Services” shall not be funded. |
| 3. | The cost for the preparation of the clinical phase (working packets 6 and 7) are funded with loans. |
| 4. | A continued funding of this project in this form is not planned. The clinical work planned for the 4th project year may be submitted in the program line KLIPHA. |
§ 7 Disbursement of the funds
| 7.1 | The first installment in the amount of 50% of the promised funds will be disbursed after signature of the Funding Contract and fulfillment of the terms and conditions stipulated in § 6. |
The second installment in the amount of 30% will be disbursed after the approval of an interim report and an interim statement in which 50% of the approved total costs must be documented, as well as after fulfillment of the terms and conditions stipulated in
§ 6.
The final installment in the amount of 20% of the total promised funds will be disbursed only after fulfillment of all terms and conditions (final account, final reports, etc.) and after the audit and approval of the statement of use (discharge) by the FFG.
| 7.2 | The funds will be transferred to the following account of the Funding Recipient |
| Account holder: | ARSANIS Biosciences GmbH | |
| Name of the bank: | ||
| IBAN: | ||
| BIC/SWIFT: |
§ 8 Reporting obligations
| 8.1 | According to Point 3 of the General Funding Terms and Conditions, the Funding Recipient must inform the FFG about the execution of the promoted project by submitting technical reports (interim and final reports) and billing statements. The reports and billing statements must be submitted via eCall (xxxxx://xxxxx.xxx.xx). The use of the forms to be found in eCall is mandatory. Other documents might have to be submitted at the request of the FFG. |
§ 9 Amendments
| 9.1 | Changes to this agreement may be made only explicitly and in writing. This shall apply also to any deviation from this requirement. |
./5
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0000 Xxxxxx |
Phone +43(0)5 7755 - 0 Fax +43 (0) 5 7755 -97900 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a Comm. Court Vienna |
FFG
Project no. 841918/30000 SCK/SAI
Page 5
| 9.2 | Under special circumstances changes to the stipulated terms and conditions may, if necessary, be made later by mutual agreement in the form of written addenda if special circumstances are present and after a new advisory board decision. |
§ 10 Legal liability
| 10.1 | The Funding Recipient shall be unconditionally liable to the FFG for compliance with all contractual provisions. The Funding Recipient shall also be liable for the conduct of third parties for which it is responsible (e.g. owners, corporate officers, etc.). The Funding Recipient must hold the FFG harmless against third parties. |
§ 11 Severability clause
| 11.1 | In the event that be a provision of this Funding Contract is invalid, such event shall not affect the validity of the remaining provisions of the Funding Contract. The contractual partners undertake to replace an invalid provision by such provision as comes closest to the purpose of this Funding Contract. |
§ 12 Applicable law
| 12.1 | This agreement and all its attachments shall be governed by Austrian law to the exclusion of the reference norms of the Austrian IPRG. |
§ 13 Legal venue
| 13.1 | The legal venue agreed upon with regard to all legal disputes arising from the funding grant shall be the materially competent court in Vienna. The FFG reserves the right to take action against the Funding Recipient also at the latter’s general legal venue. |
§ 14 Integral parts of the contract
| 14.1 | The following documents are an integral part of the Funding Contract: |
| • | The funding application submitted via eCall (“Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections”) as amended on 5/2/2013 |
| • | General terms and conditions for Funding Contracts as amended (version 1 of 2013) |
| • | FFG Guidelines – Base Programs as amended (3/22/2012) |
| • | Guide for the Treatment of Project Costs in Funding Applications and Reports for Projects with Funding Contracts according to the RTD Directives and the FFG Directives, version 1.3. |
14.2 The legal bases of this Funding Contract are in particular:
| • | Implementation Act of the Österreichische Forschungsförderungsgesellschaft mbH (Research Promotion Structural Reform Act), as amended |
| • | Guidelines of the Österreichische Forschungsförderungsgesellschaft mbH for promoting research, technology, development and innovation (FFG Guidelines GZ: BMVIT 609.986/0005- |
./6
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0000 Xxxxxx |
Phone +43(0)5 7755 - 0 Fax +43 (0) 5 7755 -97900 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a Comm. Court Vienna |
FFG
Project no. 841918/30000 SCK/SAI
Page 6
III/12/2008 and BMWA-98.310/0032-C1/10/2008)
The Funding Recipient confirms being aware of all contract components and accepts them unconditionally.
It is pointed out that this funding offer is considered revoked if the Funding Recipient does not sign it and return it to the FFG within 3 months.
For the Funding Agency:
Österreichische Forschungsförderungsgesellschaft mbH (FFG)
[stamp:] Austrian Research Promotion Agency
Vienna, on 7/1/2013
| /s/ Dr. Xxxxxxxxx Egerth-Stadlhuber |
/s/ Xx. Xxxxx Pseiner | |
| Dr. Xxxxxxxxx Egerth-Stadlhuber Director |
Xx. Xxxxx Pseiner Director |
Funding Recipient
| Vienna, on 8/6/2013 |
ARSANIS | |
| Biosciences GmbH | ||
| MarxBox | ||
| Xxxxxx-Qualtinger—Xxxxx 0 | ||
| 0000 Xxxxxx |
| /s/ Xx. Xxxxxx Xxxx | ||
| (company name, please indicate name and position in block letters, company seal) | ||
| Xx. Xxxxxx Xxxx, Director |
Attachments:
Guidelines for the Österreichische Forschungsförderungsgesellschaft mbH for promoting research, technology, development and innovation (FFG Guidelines) per link xxxxx://xxx.xxx.xx/Xxxxxxxxxx-Xxxxxxxxxxx
General terms and conditions for Funding Contracts as amended (version 1 of 2013)
FFG Guidelines – Base Programs, as amended (3/22/2012)
Guide for the Treatment of Project Costs in Funding Applications and Reports for Projects with Funding Contracts according to the RTD Directives and the FFG Directives, version 1.3.
./7
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0000 Xxxxxx |
Phone +43(0)5 7755 - 0 Fax +43 (0) 5 7755 -97900 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a Comm. Court Vienna |
FFG
Project no. 841918/30000 SCK/XXX
XXXXXXX Biosciences GmbH
Attn.: Xx. Xxxxxx Xxxx
Xxxxxx-Xxxxxxxxxx-Xxxxx 0
0000 Xxxxxx
Account statement per 12/31/2013
Project 841918
Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections
| Account no.: |
00000000 | |
| Fiscal year: |
2013 | |
| Redemption amount (EUR): |
1,244,928.00 | |
| Date of redemption: |
6/30/2020 | |
| Interest rate: |
0.75% |
| Balance per 12/31/2013 (EUR) | 0.00 | |||
| Reference dates | Description of the transaction | Transacted amount (EUR) | ||
| 3/10/2013 | 841918 DA Installment 1 GP basis | -1,251,500.00 | ||
| 12/2/2013 | 841918 Int. 0.75% per 12/31/13 | -2,324.00 | ||
| 12/31/2013 | 841918 Int. 0.75% per 12/31/13 | 2,324.00 | ||
| Debited amount (EUR) | 1,253,824.00 | |||
| Deposited amount (EUR) | 2,324.00 | |||
| Balance per 12/31/2014 (EUR) | -1,251,500.00 | |||
./8
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0000 Xxxxxx |
Phone +43(0)5 7755 - 0 Fax +43 (0) 5 7755 -97900 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a Comm. Court Vienna |
FFG
Project no. 841918/30000 SCK/XXX
XXXXXXX Biosciences GmbH
Attn.: Xx. Xxxxxx Xxxx
Xxxxxx-Xxxxxxxxxx-Xxxxx 0
0000 Xxxxxx
Account statement per 12/31/2014
Project 841918
Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections
| Account no.: |
00000000 | |
| Fiscal year: |
2014 | |
| Redemption amount (EUR): |
1,244,928.00 | |
| Date of redemption: |
6/30/2020 | |
| Interest rate: |
0.75% |
| Balance per 12/31/2013 (EUR) | -1,251,500.00 | |||
| Reference dates | Description of the transaction | Transacted amount (EUR) | ||
| 6/2/2014 | 841918 Int. 0.75% per 6/30/14 | -4,723.00 | ||
| 6/30/2014 | 841918 Int. 0.75% per 6/30/14 | 4,723.00 | ||
| 7/10/2014 | 841918 Amortization | 6,572.00 | ||
| 12/1/2014 | 841918 Int. 0.75% per 12/31//14 | -4,778.00 | ||
| 12/31/2014 | 841918 Int. 0.75% per 12/31/14 | 4,778.00 | ||
| Debited amount (EUR) | 9,501.00 | |||
| Deposited amount (EUR) | 16,073.00 | |||
| Balance per 12/31/2014 (EUR) | -1,244,928.00 | |||
./9
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0000 Xxxxxx |
Phone +43(0)5 7755 - 0 Fax +43 (0) 5 7755 -97900 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a Comm. Court Vienna |
FFG
Project no. 841918/30000 SCK/XXX
XXXXXXX Biosciences GmbH
Attn.: Xx. Xxxxxx Xxxx
Xxxxxx-Xxxxxxxxxx-Xxxxx 0
0000 Xxxxxx
Account statement per 10/31/2015
Project 841918
Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections
| Account no.: |
00000000 | |
| Fiscal year: |
2015 | |
| Redemption amount (EUR): |
1,244,928.00 | |
| Date of redemption: |
6/30/2020 | |
| Interest rate: |
0.75% |
| Balance per 12/31/2014 (EUR) | -1,244,928.00 | |||
| Reference dates | Description of the transaction | Transacted amount (EUR) | ||
| 6/1/2015 | 841918 Int. 0.75% per 6/30/15 | -4,698.00 | ||
| 6/30/2015 | 841918 Int. 0.75% per 6/30/15 | 4,698.00 | ||
| Debited amount (EUR) | 4,698.00 | |||
| Deposited amount (EUR) | 4,698.00 | |||
| Balance per 12/31/2015 (EUR) | -1,244,928.00 | |||
./10
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0000 Xxxxxx |
Phone +43(0)5 7755 - 0 Fax +43 (0) 5 7755 -97900 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a Comm. Court Vienna |
FFG
Project no. 841918/30000 SCK/XXX
XXXXXXX Biosciences GmbH
Attn.: Xx. Xxxxxx Xxxx
Xxxxxx-Xxxxxxxxxx-Xxxxx 0
0000 Xxxxxx
Account statement per 12/31/2014
Project 841918
Development of human monoclonal antibody-based products against severe hospital-associated bacterial infections
| Account no.: | 00000000 | |
| Fiscal year: | 2014 | |
| Reclaim (EUR): | 0 |
| Balance per 12/31/2013 (EUR) | 0.00 | |||
| Reference dates | Description of the transaction | Transacted amount (EUR) | ||
| 7/7/2014 | 841918 FB reclaims | -1,537.00 | ||
| 7/7/2014 | 841918 FB interest | -10.00 | ||
| 7/10/2014 | 841918 FB redemption | 1,537.00 | ||
| 7/10/2014 | 841918 FB interest | 10.00 | ||
| Debited amount (EUR) | 1,547.00 | |||
| Deposited amount (EUR) | 1,547.00 | |||
| Balance per 12/31/2014 (EUR) | 0.00 | |||
./11
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0000 Xxxxxx |
Phone +43(0)5 7755 - 0 Fax +43 (0) 5 7755 -97900 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a Comm. Court Vienna |
